Clinical Trial Update: A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia [Phase 2]

View source ↗

Summary

A Phase II dose-escalation study evaluated the pharmacokinetics of eltrombopag in pediatric patients with previously untreated or relapsed/recurrent severe apla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Aplastic Anemia | Phase 2 | Status: COMPLETED